Dr Haruyasu Murakami, of the Shizuoka Cancer Center, Shizuoka, Japan, told the meeting: “Preliminary results from this study show a high overall response rate of 78%, with tumours shrinking in seven out of nine patients who had both the EGFR and T790M mutations. While the number of patients is still small, this response is comparable with two other drugs in development that target EGFR – CO-1689 and AZ-9291 – but ASP8273 has fewer safety concerns than these drugs.”
The most common adverse reactions to ASP8273 were mild cases of diarrhoea (in half of the patients), nausea and vomiting (in a third of the patients).
There were none of the severe respiratory complications, heart problems and high blood sugar levels that have occurred during the clinical trials of the other two drugs.
这个药早期数据不错，副作用小，orr能到78%。
可惜是小日本做的，不知道数据是否准确。 |
显身卡
